DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.
By C. Iacobuzio-Donahue, Baojin Fu, S. Yachida, Mingde Luo, H. Abe, Clark M. Henderson, F. Vilardell, Z. Wang, J. Keller, P. Banerjee and 10 more. Journal of Clinical Oncology, 2009
1,018 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/1c41c2a1a420c49329980b340d6c7e113bce07d7
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- A patient-level meta-analysis of FOLFIRINOX for locally advanced pancreatic cancer (2016, background): “The rationale of (chemo)radiation is that about 30% of pancreatic cancer patients die from local progression in the absence of metastatic disease.(40) LAPC patients who do not develop metastatic disease during systemic treatment might benefit from local control of the tumor with (chemo)radiation.”
- Recent progress in pancreatic cancer (2013, background): “associated with poor prognosis and with more widely metastatic disease.(85,86)”
- Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma (2017, background): “Although most patients will die from distant disease, localized disease can lead to death in up to 30% of PDAC patients.(13) Furthermore, local recurrence can be debilitating due to symptoms resulting from locally destructive growth, highlighting the importance of local tumor control even after rese”
- Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. (2014, methodology): “However, undifferentiated tumors comprise approximately 5%–10% of all advanced PDAC (Iacobuzio-Donahue et al., 2009).”